



The Drug Utilization Review (DUR) Board Reviewed  
the Following New Drugs/Classes on  
March 5, 2019

| <b>Therapeutic Class</b>            | <b>Drug Name</b>                            | <b>DURB Recommendations</b>     |
|-------------------------------------|---|---------------------------------|
| <b>Immunomodulators, Asthma</b>     |   |                                 |
|                                     | <i>Fasenra (Subcutaneous) Injection</i>     | Defer to future meeting         |
| <b>Potassium Binders</b>            |   |                                 |
|                                     | <i>Lokelma (Oral) Powder for Suspension</i> | NP/PA                           |
| <b>Opiate Dependence Treatments</b> |   |                                 |
|                                     | <i>Lucemyra (Oral) Tablets</i>              | NP/PA                           |
| <b>Uterine Disorder Treatments</b>  |   |                                 |
|                                     | <i>Orilissa (Oral) Tablets</i>              | P/PA                            |
| <b>Antibiotics, Vaginal</b>         |   |                                 |
|                                     | <i>Solosec (Oral) Granules</i>              | NP/PA                           |
| <b>Aminoglycosides</b>              |   |                                 |
|                                     | <i>Zemdri (Intravenous) Injection</i>       | P/PA (for coverage on the PADL) |

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization;  
PADL=Providers' Administered Drug List